Furthermore, CD44+/CD24− was found to be present in 50% of pretreatment tumor biopsies of patients with residual EAC after treatment in surgical specimens but absent in all biopsies of patients who had a pathological complete response after nCRT [16]. The gene discussed is CD44; the disease is neoplasm.